Authors' objectives:

To analyse available scientific knowledge regarding the anti-GD monoclonal antibody in the treatment of patients with high risk neuroblastoma and to assess the possibility of performing this treatment in a reference centre in our country or the inclusion of these patients in international multicenter clinical trials currently underway.

Authors' recommendations: Available scientific evidence on immunotherapy with anti-GD2 in patients with high risk neuroblastoma is limited and low quality (level of evidence 3), its grade of recommendation being of D in accordance with the SIGN system. A certain benefit from treatment with monoclonal antibodies is observed in patients with progression-free disease. At present, this treatment cannot be recommended as standard therapy in patients with high risk neuroblastoma due to the low quality of available scientific knowledge. Taking into account the existence of international multicenter randomized clinical trials currently underway, it is recommended that participation in these studies be always conducted under the scope of a clinical research protocol following all corresponding legal and administrative requirements.

Project Status: Completed

URL for project: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/antigd2_neuroblastoma_pcsns_aatrm2010.pdf

Year Published: 2010

URL for published report: http://www.gencat.cat/salut/depsan/units/aatrm/html/en/dir393/doc13671.html

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Spain

Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya

Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510

Contact Name: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net

Contact Email: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net

Copyright: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)